表紙
市場調査レポート

米国の整形外科用バイオマテリアル市場

US Orthopedic Biomaterials Market - 2011-2021

発行 iData Research Inc. 商品コード 322310
出版日 ページ情報 英文 288 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。

ご注意: Single Userライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
認証されたPC上のみでの閲覧となっております。

Back to Top
米国の整形外科用バイオマテリアル市場 US Orthopedic Biomaterials Market - 2011-2021
出版日: 2015年01月01日 ページ情報: 英文 288 Pages
概要

米国の整形外科用バイオマテリアル市場は、今後も拡大傾向を保ち、2021年には39億米ドルの規模に達する、と予想されています。特に幹細胞(幹細胞移植片、骨髄濃縮物)市場の成長率が最も高くなると見込まれています。その他の部門も概ね、今後の急成長が見込まれていますが、規制緩和が実施されれば、潜在的な市場成長率は更に高まるものと期待されています。

当レポートでは、米国における整形外科用の各種バイオマテリアルの市場について分析し、全体的な市場構造や処置件数の推移(症状別・素材別)、素材別の詳細な市場動向・構造(促進/阻害要因、競争動向ほか)などを調査・推計しております。

エグゼクティブ・サマリー

分析手法

米国の整形外科用バイオマテリアル市場の概況

  • イントロダクション
  • 市場概況
  • 部門別の動向分析
  • 市場促進・抑制要因
  • 競合分析
  • ハーフィンダール指数(市場集中度)
  • 企業合併・買収(M&A)

処置件数

  • 「処置」の定義
  • 骨移植の処置件数:種類別
  • 代替骨移植片の処置件数
  • 骨移植用形成因子の処置件数
  • 骨移植用幹細胞の処置件数
  • 細胞療法の処置件数
  • ヒアルロン酸治療の件数:種類別
  • 軟骨再建の処置件数:種類別
  • 脊椎用の機械加工式・自己骨移植片の処置件数:種類別

代替骨移植片の市場

  • イントロダクション
  • 市場の分類
    • 症状別
    • 素材別
  • 処置件数
    • 素材別の処置件数
    • 処置1件当たり使用量:症状別
  • 市場概況
    • 症状別
    • 素材別
  • 市場分析・予測
    • 全体的な市場規模
    • 素材別の市場規模
      • 全体的規模
      • 自己骨移植片
      • 脱灰骨移植片
      • 合成骨移植片
    • 症状別の市場規模
      • 脊椎用骨移植片
      • 外傷用骨移植片
      • 大関節再建用骨移植片
      • 足関節再建用骨移植片
      • 頭蓋顎顔面(CMF)用骨移植片
      • 腫瘍用骨移植片
  • 市場促進・抑制要因
  • 競合分析

骨形成因子市場

  • イントロダクション
  • 市場分析・予測
  • 市場促進・抑制要因
  • 競合分析

幹細胞市場

  • イントロダクション
  • 市場概要
  • 市場分析・予測
    • 市場全体
    • 頚椎幹細胞市場
    • 腰椎幹細胞市場
  • 市場促進・抑制要因
  • 競合分析

細胞療法市場

  • イントロダクション
  • 市場概要
  • 市場分析・予測
    • 多血小板血漿(PRP)の全体的市場
    • 骨髄濃縮物の全体的市場
  • 市場促進・抑制要因
  • 競合分析

ヒアルロン酸関節内補充治療市場

  • イントロダクション
  • 市場概要
  • 市場分析・予測
    • ヒアルロン酸関節内補充治療の全体的市場
    • 単回投与式治療法の市場
    • 3回投与式治療法の市場
    • 5回投与式治療法の市場
  • 市場促進・抑制要因
  • 競合分析

軟骨再建市場

  • イントロダクション
  • 市場概要
  • 市場分析・予測
    • 骨軟骨自家移植片市場
    • 半月板自家移植片市場
    • 軟骨細胞自家移植市場
    • 若年性微粒子化軟骨向け自家移植片市場
  • 市場促進・抑制要因
  • 競合分析

脊椎用・機械加工式骨移植片市場

  • イントロダクション
  • 市場概要
  • 市場分析・予測
    • 全体的な市場規模
    • 前方椎体間固定術(ALIF)市場
    • 後方椎体間固定術(PLIF)市場
    • 経椎間孔椎体固定術(TLIF)市場
    • 頚部椎体間固定術(CIF)市場
  • 市場促進・抑制要因
  • 競合分析

略語集

目次
Product Code: iDATA_USOB15_RPT

The U.S. orthopedic biomaterials market will undergo increasing growth through 2021, resulting in a market value of nearly $3.9 billion by that year.

The U.S. orthopedic biomaterials market includes bone graft substitutes, growth factors, orthopedic stem cells, cell therapy, hyaluronic acid viscosupplementation, cartilage repair and machined bone allografts. The fastest growing segments involve stem cells, namely the segments for stem cell bone grafts and concentrated bone marrow. The products within these markets offer the greatest regenerative potential for healing bone.

Growth factors and spinal machined bone allografts represented the only decreasing markets in 2014, but the growth factor market will start to increase again by 2017. The markets for growth factors, hyaluronic acid viscosupplementation and cartilage repair will see accelerating growth over the forecast period. Overall, if regulatory barriers can be overcome, there will be much potential for technological development and product introduction.

image1

Orthopedic Bone Graft Substitute Market

The bone graft substitute market will trend away from allografts and towards the more lucrative demineralized bone matrix and synthetic grafts. This market will grow at a 3.4% CAGR through 2021.

The bone graft substitute market consists of allograft, demineralized bone matrix and synthetic materials. Bone grafts are used in a variety of indications including spinal fusion, trauma, large joint reconstruction, foot reconstruction, as well as craniomaxillofacial and oncological applications.

The bone graft substitute market competes with both the growth factor market, which is currently only comprises INFUSE®, and the stem cell graft market. Due to the declining usage of INFUSE®, the use of bone graft substitute use has increased. The rise of cell therapy products, including platelet-rich-plasma and bone marrow concentrate, has also aided the growth of the bone graft substitute market, especially in the segments for demineralized bone matrices and synthetic grafts. Platelet-rich plasma provides growth factors when a graft is soaked in it; bone marrow concentrate provides stem cells. This complementary use allows bone graft substitutes to better compete with the growth factors and stem cell grafts.

While allografts are already considered a commodity product, the commodification process is occurring for demineralized bone grafts as well. Pricing pressure thus exists across all segments, including the segment for including the more expensive synthetic grafts.

image2

Orthopedic Growth Factor Market

The orthopedic growth factor market has been declining since 2010; however, the market was still valued at nearly $372 million in 2014.

This market is declining because of safety concerns over Medtronic's INFUSE® growth factor graft. A number of lawsuits have also been raised that have negatively affected public opinion of the product. INFUSE® was initially met with great success; for this reason, the product came to be used for unapproved indications. The market now recedes back to a size reflective of its approved indications; it will settle and see growth again by 2017.

The decline in this market has notably prompted the market growth for alternative grafts such as demineralized bone matrices, synthetics and stem cell grafts. Nevertheless, as INFUSE® remains the only growth factor product, there will remain a solid interest in the product until alternatives are developed. Counteracting such development, however, is the capacity of a bone graft to be soaked with platelet-rich plasma, thereby providing the graft with growth factors such as bone morphogenetic protein (BMP).

image3

Orthopedic Stem Cell Market

The buzz over orthopedic stem cells is reflected in that segment's rapid growth. In 2014 alone, the orthopedic stem cell market grew by more than 17%.

Bone repair is about osteoconduction, osteoinduction and osteogenesis. Stem cell grafts offer a complete solution in that they provide all three: scaffolding, signaling and innate stem cells capable of developing into bone. In cases where assured bone repair is required, such as with elderly patients undergoing a lumbar or cervical fusion, the best options may indeed be stem cell grafts.

Because development and FDA approval costs are so high, stem cell products feature premium pricing. On average, pricing is over $2,000 more than a demineralized or synthetic graft, and over $3,000 more than a typical mineralized allograft. This pricing will prevent the usage of stem cells for indications necessitating a large amount of graft, such as with trauma, hip or oncology applications.

Currently, stem cell products are only considered to be used for lumbar and cervical spinal procedures. If prices were to fall, the stem cell market may see increasingly rapid growth as the number of feasible indications grows.

image4

Orthopedic Cell Therapy Market

The cell therapy market features segments for both platelet-rich plasma and bone marrow concentrate, with the latter projected to experience a rapid 11.6% CAGR in the number of treatments.

The orthopedic cell therapy market grew very slightly in 2014 due to ASP decreases for both the plateletrich plasma and bone marrow concentrate segments. The platelet-rich plasma segment previously experienced rapid ASP declines due to smaller volume products and from competition due to Arthrex's low cost ACP® system. A similar trend is occurring within the bone marrow concentrate segment, where prices will continue to drop as they near the $1,000 price point.

Platelet-rich plasma is mostly utilized as an injection, not for soaking bone graft. Injectable treatments are used in wound repair, sports medicine and a growing number of plastic surgeries. Nearly 60% of bone marrow concentrate is used for spinal indications.

Collectively, the cell therapy market is growing for two reasons. First, INFUSE® use is declining. Second, there is increasing complementary use of cell therapy products in the growing demineralized and synthetic bone graft markets.

image5

Orthopedic Hyaluronic Acid Viscosupplementation Market

As the five injection segment was cannibalized by the three injection segment, now the three injection segment is giving way to the single injection segment. The single injection treatment segment will be the largest in this market by 2020.

The hyaluronic acid viscosupplementation market consists of injections which provide pain relief for osteoarthritis of the knee. The treatments were first developed to involve five injections before three injection treatments came about. Most recently, single injection treatments were developed in 2009.

Each treatment occurs once a week. If pain relief can be achieved with products that require fewer trips to the doctor, then such a product would presumably be preferred. This is largely why three injection, and more recently single injection, treatments have come to dominate the market.

However, some patients do not respond as well to single injection treatments. Side effects such as inflammation or stiffness can occur. Furthermore, some patients do not find pain relief without multiple injections. Despite the market's shift to single injection products, there will be a demand for multi injection products.

The three injection segment will remain larger than the single injection segment up until 2020.

image6

Orthopedic Cartilage Repair Market

Growth of the cartilage repair market is limited by the efficacy and price of microfracture procedures. Segments for emerging technologies, such as that of microfracture adjunct products, are expected to see double-digit growth.

The use of allograft or cartilage implants only accounted for just over 6% of all cartilage repair procedures in 2014. The efficacy of a cartilage repair technique is always compared to the success of a microfracture procedure, which provides reasonable relief and is cheap to perform. A cartilage repair implant, which is likely to feature a high price to cover development costs, must justify the premium pricing with sufficiently superior results. This price premium is why most cartilage repair segments are growing at a slow rate.

However, one exception is the microfracture adjunct market. Instead of supplanting microfracture, products from this market are to improve results, while only marginally increasing procedural cost. The only such product on the market in the U.S. currently is BioCartilage®. Another option to enhance microfracture is DeNovo®, but this product is six times more expensive than BioCartilage® as it is sourced from juvenile cartilage and is described as having 10x the chondrocyte density of adult tissue. Many cartilage products are in development, but will need to overcome the value that microfracture provides.

image7

Spinal Machined Bone Allograft Market

The spinal machined bone allograft market has been declining with the rise of minimally invasive and motion preservation options. This market declined to just over $293 million in 2014.

The spinal machined bone allograft market consists of segments for spinal fusion of the lumbar region performed from an anterior, posterior or transforaminal approach, as well as spinal fusion of the cervical region of the spine. Machined bone allografts compete directly with the usage of PEEK and metal interbody devices. However, a declining interest in spinal fusion is putting the market under pressure.

Machined bone allograft segments are experiencing pricing pressures for all techniques, resulting in ASP declines across the board. The indications for spinal fusion have increased from scoliosis and disc degeneration, but now spinal fusion is being seen as a less than favorable option especially when revision rates and complications prevent it from being a complete solution. Less invasive options and physical therapy to stave off spinal fusion are pushing the market down. This trend is a common feature for the orthopedic market in general where joint fusion is often superseded by replacement as technology advances sufficiently.

image8

Leading Competitors

The niche nature of many segments within the overall orthopedic biomaterials market mean that they are often fairly concentrated, with an average Herfindahl Index of 0.36.

Despite the concentration of some individual markets, the overall orthopedic biomaterials market has a great deal of participating competitors, with only Medtronic and Genzyme holding a double-digit shares of the market. The average number of competitors per market, excluding the bone graft substitute market, is just larger than 5, again indicating the concentrated nature of the biomaterials market.

Medtronic led the overall market because of its performance in bone graft substitutes, machined bone allografts and a monopoly of the growth factor market. Despite the rapid decline of the growth factor market in recent years, its respectable size ensures a strong position for Medtronic.

Genzyme follows Medtronic in market share due to its sole presence in the large hyaluronic acid market, but its share in the growing single injection segment may be at risk from newer entrants, especially the DePuy Synthes marketed Monovisc™ from Anika Therapeutics.

Participants in the stem cell graft market will likely experience an increase in share as that market grows rapidly over the forecast period. In contrast, those in the shrinking machined bone allograft market will see declining shares of the overall orthopedic biomaterials market.

image9

Table of Contents

TABLE OF CONTENTS

LIST OF FIGURES

LIST OF CHARTS

EXECUTIVE SUMMARY

  • 1.1 U.S. MARKET FOR ORTHOPEDIC BIOMATERIALS
  • 1.2 ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET
  • 1.3 ORTHOPEDIC GROWTH FACTOR MARKET
  • 1.4 ORTHOPEDIC STEM CELL MARKET
  • 1.5 ORTHOPEDIC CELL THERAPY MARKET
  • 1.6 ORTHOPEDIC HYALURONIC ACID VISCOSUPPLEMENTATION MARKET
  • 1.7 ORTHOPEDIC CARTILAGE REPAIR MARKET
  • 1.8 SPINAL MACHINED BONE ALLOGRAFT MARKET
  • 1.9 LEADING COMPETITORS

RESEARCH METHODOLOGY

  • 2.1 RESEARCH SCOPE
  • 2.2 IDATA'S 9-STEP METHODOLOGY
    • Step 1: Project Initiation & Team Selection
    • Step 2: Prepare Data Systems and Perform Secondary Research
    • Step 3: Preparation for Interviews & Questionnaire Design
    • Step 4: Performing Primary Research
    • Step 5: Research Analysis: Establishing Baseline Estimates
    • Step 6: Market Forecast and Analysis
    • Step 7: Identify Strategic Opportunities
    • Step 8: Final Review and Market Release
    • Step 9: Customer Feedback and Market Monitoring

U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW

  • 3.1 INTRODUCTION
    • 3.1.1 Bone Graft Substitutes
    • 3.1.2 Growth Factors
    • 3.1.3 Orthopedic Stem Cell Therapy
    • 3.1.4 Cell Therapies
    • 3.1.5 Hyaluronic Acid Viscosupplementation
    • 3.1.6 Cartilage Repair
    • 3.1.7 Spinal Machined Bone Allografts
  • 3.2 MARKET OVERVIEW
  • 3.3 TREND ANALYSIS BY SEGMENT
  • 3.4 DRIVERS AND LIMITERS
    • 3.4.1 Market Drivers
    • 3.4.2 Market Limiters
  • 3.5 COMPETITIVE ANALYSIS
  • 3.6 HERFINDAHL INDEX
  • 3.7 MERGERS AND ACQUISITIONS

PROCEDURE NUMBERS

  • 4.1 PROCEDURAL DEFINITIONS
  • 4.2 BONE GRAFT PROCEDURE NUMBERS BY TYPE
  • 4.3 BONE GRAFT SUBSTITUTE PROCEDURE NUMBERS
    • 4.3.1 By Material
    • 4.3.2 By Indication
  • 4.4 GROWTH FACTOR BONE GRAFT PROCEDURE NUMBERS
  • 4.5 STEM CELL BONE GRAFT PROCEDURE NUMBERS
  • 4.6 CELL THERAPY TREATMENT NUMBERS
    • 4.6.1 Overview by Type
    • 4.6.2 Platelet-Rich Plasma Treatment Numbers by Indication
    • 4.6.3 Bone Marrow Concentrate Treatment Numbers by Indication
  • 4.7 HYALURONIC ACID TREATMENT NUMBERS BY TYPE
  • 4.8 CARTILAGE REPAIR PROCEDURE NUMBERS BY TYPE
  • 4.9 SPINAL MACHINED BONE ALLOGRAFT PROCEDURE NUMBERS BY APPROACH

ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET

  • 5.1 INTRODUCTION
  • 5.2 MARKET SEGMENTATION
    • 5.2.1 By Indication
      • 5.2.1.1 Spine
      • 5.2.1.2 Trauma
      • 5.2.1.3 Large Joint
      • 5.2.1.4 Foot Reconstruction
      • 5.2.1.5 Craniomaxillofacial
      • 5.2.1.6 Oncology
    • 5.2.2 By Material
      • 5.2.2.1 Autograft
      • 5.2.2.2 Standard Allograft
      • 5.2.2.3 Demineralized Bone Matrix
      • 5.2.2.4 Synthetic
      • 5.2.2.5 Xenograft
  • 5.3 PROCEDURE NUMBERS
    • 5.3.1 Bone Graft Substitutes Procedure Numbers by Material
    • 5.3.2 Units Per Procedure by Indication
  • 5.4 MARKET OVERVIEW
    • 5.4.1 Bone Graft Substitute Market by Material
    • 5.4.2 Bone Graft Substitute Market by Indication
  • 5.5 MARKET ANALYSIS AND FORECAST
    • 5.5.1 Total Orthopedic Bone Graft Substitute Market
    • 5.5.2 Bone Graft Substitute Market by Material
      • 5.5.2.1 Total Allograft Bone Graft Substitute Market
      • 5.5.2.2 Allograft Bone Graft Substitute Market by Indication
        • 5.5.2.2.1 Spine
          • 5.5.2.2.1.1 Cervical Spine
          • 5.5.2.2.1.2 Thoracolumbar Spine
        • 5.5.2.2.2 Trauma
          • 5.5.2.2.2.1 Non-union Trauma
          • 5.5.2.2.2.2 Fresh Fracture Trauma
        • 5.5.2.2.3 Large Joint Reconstruction
          • 5.5.2.2.3.1 Hip Large Joint Reconstruction
          • 5.5.2.2.3.2 Knee Large Joint Reconstruction
        • 5.5.2.2.4 Foot Reconstruction
        • 5.5.2.2.5 Craniomaxillofacial
        • 5.5.2.2.6 Oncology
          • 5.5.2.3 Total Demineralized Bone Matrix Market
          • 5.5.2.4 Demineralized Bone Matrix Market, with and without Carriers
          • 5.5.2.5 Demineralized Bone Matrix Market by Indication
        • 5.5.2.5.1 Spine
          • 5.5.2.5.1.1 Cervical Spine
          • 5.5.2.5.1.2 Thoracolumbar Spine
        • 5.5.2.5.2 Trauma
          • 5.5.2.5.2.1 Non-union Trauma
          • 5.5.2.5.2.2 Fresh Fracture Trauma
        • 5.5.2.5.3 Large Joint Reconstruction
          • 5.5.2.5.3.1 Hip Large Joint Reconstruction
          • 5.5.2.5.3.2 Knee Large Joint Reconstruction
        • 5.5.2.5.4 Foot Reconstruction
        • 5.5.2.5.5 Craniomaxillofacial
        • 5.5.2.5.6 Oncology
          • 5.5.2.6 Total Synthetic Bone Graft Substitute Market
          • 5.5.2.7 Synthetic Bone Graft Substitute Market by Indication
        • 5.5.2.7.1 Spine
          • 5.5.2.7.1.1 Cervical Spine
          • 5.5.2.7.1.2 Thoracolumbar Spine
        • 5.5.2.7.2 Trauma
          • 5.5.2.7.2.1 Non-union Trauma
          • 5.5.2.7.2.2 Fresh Fracture Trauma
        • 5.5.2.7.3 Large Joint Reconstruction
          • 5.5.2.7.3.1 Hip Large Joint Reconstruction
          • 5.5.2.7.3.2 Knee Large Joint Reconstruction
        • 5.5.2.7.4 Foot Reconstruction
        • 5.5.2.7.5 Craniomaxillofacial
        • 5.5.2.7.6 Oncology
    • 5.5.3 Bone Graft Substitute Market by Indication
      • 5.5.3.1 Spine Bone Graft Substitute Market
        • 5.5.3.1.1 Cervical Spine Bone Graft Substitute Market
        • 5.5.3.1.2 Thoracolumbar Spine Bone Graft Substitute Market
      • 5.5.3.2 Trauma Bone Graft Substitute Market
        • 5.5.3.2.1 Non-union Trauma Fracture Bone Graft Substitute Market
        • 5.5.3.2.2 Fresh Fracture Trauma Bone Graft Substitute Market
      • 5.5.3.3 Large Joint Reconstruction Bone Graft Substitute Market
        • 5.5.3.3.1 Hip Large Joint Reconstruction Bone Graft Substitute Market
        • 5.5.3.3.2 Knee Large Joint Reconstruction Bone Graft Substitute Market
    • 5.5.3.4 Foot Reconstruction Bone Graft Substitute Market
    • 5.5.3.5 Craniomaxillofacial Bone Graft Substitute Market
    • 5.5.3.6 Oncology Bone Graft Substitute Market
  • 5.6 DRIVERS AND LIMITERS
    • 5.6.1 Market Drivers
      • 5.6.1.1 Allograft Bone Graft Substitute Market
      • 5.6.1.2 Demineralized Bone Matrix Bone Graft Substitute Market
      • 5.6.1.3 Synthetic Bone Graft Substitute Market
    • 5.6.2 Market Limiters
      • 5.6.2.1 Allograft Bone Graft Substitute Market
      • 5.6.2.2 Demineralized Bone Matrix Bone Graft Substitute Market
      • 5.6.2.3 Synthetic Bone Graft Substitute Market
  • 5.7 COMPETITIVE ANALYSIS

ORTHOPEDIC GROWTH FACTOR MARKET

  • 6.1 INTRODUCTION
    • 6.1.1 BMP-2 (Medtronic)
    • 6.1.2 BMP-7 (Olympus Biomaterials)
  • 6.2 MARKET ANALYSIS AND FORECAST
  • 6.3 DRIVERS AND LIMITERS
    • 6.3.1 Market Drivers
    • 6.3.2 Market Limiters
  • 6.4 COMPETITIVE ANALYSIS

ORTHOPEDIC STEM CELL MARKET

  • 7.1 INTRODUCTION
    • 7.1.1 Lineage
      • 7.1.1.1 Human Embryonic Stem Cells (hESC)
      • 7.1.1.2 Mesenchymal Stem Cells (MSC)
    • 7.1.2 Other Therapeutic Applications
  • 7.2 MARKET OVERVIEW
    • 7.2.1 Orthopedic Stem Cell Market by Anatomy
  • 7.3 MARKET ANALYSIS AND FORECAST
    • 7.3.1 Total Orthopedic Stem Cell Market
    • 7.3.2 Cervical Spine Stem Cell Market
    • 7.3.3 Lumbar Spine Stem Cell Market
  • 7.4 DRIVERS AND LIMITERS
    • 7.4.1 Market Drivers
    • 7.4.2 Market Limiters
  • 7.5 COMPETITIVE ANALYSIS

ORTHOPEDIC CELL THERAPY MARKET

  • 8.1 INTRODUCTION
    • 8.1.1 Platelet-Rich Plasma
    • 8.1.2 Concentrated Bone Marrow Aspirate
  • 8.2 MARKET OVERVIEW
  • 8.3 MARKET ANALYSIS AND FORECAST
    • 8.3.1 Total Platelet-Rich Plasma Market
      • 8.3.1.1 Soft Tissue Platelet-Rich Plasma Market
      • 8.3.1.2 Orthopedic Platelet-Rich Plasma Market
      • 8.3.1.3 Cardiac Platelet-Rich Plasma Market
      • 8.3.1.4 Spine Platelet-Rich Plasma Market
      • 8.3.1.5 Plastics Platelet-Rich Plasma Market
    • 8.3.2 Total Bone Marrow Concentrate Market
      • 8.3.2.1 Spine Bone Marrow Concentrate Market
      • 8.3.2.2 Trauma Bone Marrow Concentrate Market
      • 8.3.2.3 Soft Tissue Concentrated Bone Marrow Aspirate Market
      • 8.3.2.4 Joint Reconstruction Bone Marrow Concentrate Market
  • 8.4 DRIVERS AND LIMITERS
    • 8.4.1 Market Drivers
    • 8.4.2 Market Limiters
  • 8.5 COMPETITIVE ANALYSIS

ORTHOPEDIC HYALURONIC ACID VISCOSUPPLEMENTATION MARKET

  • 9.1 INTRODUCTION
    • 9.1.1 Benefits of Viscosupplementation
    • 9.1.2 Synovial Fluid
    • 9.1.3 Product Types
      • 9.1.3.1 Single-Injection Products
      • 9.1.3.2 Three-Injection Cycle Products
      • 9.1.3.3 Three/Five-Injection Cycle Products
    • 9.1.4 Reimbursement
  • 9.2 MARKET OVERVIEW
  • 9.3 MARKET ANALYSIS AND FORECAST
    • 9.3.1 Total Hyaluronic Acid Viscosupplementation Market
    • 9.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market
    • 9.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market
    • 9.3.4 Five-Injection Hyaluronic Acid Viscosupplementation Market
  • 9.4 DRIVERS AND LIMITERS
    • 9.4.1 Market Drivers
    • 9.4.2 Market Limiters
  • 9.5 COMPETITIVE ANALYSIS

ORTHOPEDIC CARTILAGE REPAIR MARKET

  • 10.1 INTRODUCTION
    • 10.1.1 Anatomy
    • 10.1.2 Methods for Cartilage Repair
      • 10.1.2.1 Microfracture
      • 10.1.2.2 Microfracture Adjunct
      • 10.1.2.3 Osteoarticular Autograft Transfer System
      • 10.1.2.4 Particulated Juvenile Allograft
      • 10.1.2.5 Osteochondral Allograft Transfer
      • 10.1.2.6 Autologous Chondrocyte Implantation
      • 10.1.2.7 Meniscal Allograft Transplantation
  • 10.2 MARKET OVERVIEW
  • 10.3 MARKET ANALYSIS AND FORECAST
    • 10.3.1 Osteochondral Allograft Market
    • 10.3.2 Meniscal Allograft Market
    • 10.3.3 Autologous Chondrocyte Implantation Market
    • 10.3.4 Particulated Juvenile Allograft Implant Market
    • 10.3.5 Microfracture Adjunct Market
  • 10.4 DRIVERS AND LIMITERS
    • 10.4.1 Market Drivers
    • 10.4.2 Market Limiters
  • 10.5 COMPETITIVE ANALYSIS

SPINAL MACHINED BONE ALLOGRAFT MARKET

  • 11.1 INTRODUCTION
    • 11.1.1 Anterior Lumbar Interbody Fusion (ALIF)
    • 11.1.2 Posterior Lumbar Interbody Fusion (PLIF)
    • 11.1.3 Transforaminal Lumbar Interbody Fusion (TLIF)
    • 11.1.4 Lateral Lumbar Interbody Fusion (LLIF)
    • 11.1.5 Cervical Interbody Fusion (CIF)
    • 11.1.6 Machined Bone Material
  • 11.2 MARKET OVERVIEW
  • 11.3 MARKET ANALYSIS AND FORECAST
    • 11.3.1 Total Spinal Machined Bone Allograft Market
    • 11.3.2 ALIF Machined Bone Allograft Market
      • 11.3.2.1 PLIF Machined Bone Allograft Market
      • 11.3.2.2 TLIF Machined Bone Allograft Market
      • 11.3.2.3 CIF Machined Bone Allograft Market
  • 11.4 DRIVERS AND LIMITERS
    • 11.4.1 Market Drivers
    • 11.4.2 Market Limiters
  • 11.5 COMPETITIVE ANALYSIS

ABBREVIATIONS

LIST OF FIGURES

  • Figure 3-1: Orthopedic Biomaterials Market by Segment, U.S., 2011 - 2021 (US$M)
  • Figure 3-2: Orthopedic Biomaterials Market Growth by Segment, U.S., 2011 - 2021
  • Figure 3-3: Drivers and Limiters, Orthopedic Biomaterials Market, U.S., 2014
  • Figure 3-4: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2014 (Part 1 of 2)
  • Figure 3-5: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2014 (Part 2 of 2)
  • Figure 3-6: Herfindahl Index, Orthopedic Biomaterials Market, U.S., 2014
  • Figure 4-1: Bone Graft Procedure Numbers By Type, U.S., 2011 - 2021
  • Figure 4-2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2011 - 2021
  • Figure 4-3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2011 - 2021
  • Figure 4-4: Growth Factor Bone Graft Procedure Numbers, U.S., 2011 - 2021
  • Figure 4-5: Stem Cell Bone Graft Procedure Numbers, U.S., 2011 - 2021
  • Figure 4-6: Cell Therapy Treatment Numbers by Type, U.S., 2011 - 2021
  • Figure 4-7: Platelet-Rich Plasma Treatment Numbers By Indication, U.S., 2011 - 2021
  • Figure 4-8: Bone Marrow Concentrate Treatment Numbers By Indication, U.S., 2011 - 2021
  • Figure 4-9: Hyaluronic Acid Treatment Numbers By Type, U.S., 2011 - 2021.
  • Figure 4-10: Cartilage Repair Procedure Numbers By Type, U.S., 2011 - 2021
  • Figure 4-11: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2011 - 2021
  • Figure 5-1: Bone Graft Substitute Procedure Numbers By Material, U.S., 2011 - 2021
  • Figure 5-2: Units per Procedure by Indication, Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-3: Orthopedic Bone Graft Substitute Market by Material, U.S., 2011 - 2021 (US$M)
  • Figure 5-4: Orthopedic Bone Graft Substitute Market by Indication, U.S., 2011 - 2021 (US$M)
  • Figure 5-5: Total Orthopedic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-6: Total Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-7: Allograft Bone Graft Substitute Market by Indication, U.S., 2011 - 2021 (US$M)
  • Figure 5-8: Total Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-9: Cervical Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021.
  • Figure 5-10: Thoracolumbar Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021.
  • Figure 5-11: Total Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-12: Non-union Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-13: Fresh Fracture Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-14: Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-15: Hip Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S.,2011 - 2021
  • Figure 5-16: Knee Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S.,2011 - 2021
  • Figure 5-17: Foot Reconstruction Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-18: Craniomaxillofacial Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-19: Oncology Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-20: Total Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-21: Demineralized Bone Matrix Market (with Carriers), U.S., 2011 - 2021
  • Figure 5-22: Demineralized Bone Matrix Market (without Carriers), U.S., 2011 - 2021
  • Figure 5-23: Demineralized Bone Matrix Market by Indication, U.S., 2011 - 2021 (US$M)
  • Figure 5-24: Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-25: Cervical Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-26: Thoracolumbar Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-27: Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-28: Non-union Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-29: Fresh Fracture Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-30: Large Joint Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-31: Hip Large Joint Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-32: Knee Large Joint Reconstruction Demineralized Bone Matrix Market, U.S.,2011 - 2021
  • Figure 5-33: Foot Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-34: Craniomaxillofacial Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-35: Oncology Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Figure 5-36: Total Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-37: Synthetic Bone Graft Substitute Market by Indication, U.S., 2011 - 2021 (US$M)
  • Figure 5-38: Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-39: Cervical Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-40: Thoracolumbar Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-41: Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-42: Non-union Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-43: Fresh Fracture Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-44: Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-45: Hip Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S.,2011 - 2021
  • Figure 5-46: Knee Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S.,2011 - 2021
  • Figure 5-47: Foot Reconstruction Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-48: Craniomaxillofacial Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-49: Oncology Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-50: Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-51: Cervical Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-52: Thoracolumbar Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-53: Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-54: Non-union Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-55: Fresh Fracture Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-56: Large Joint Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-57: Hip Large Joint Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-58: Knee Large Joint Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-59: Foot Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-60: Craniomaxillofacial Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-61: Oncology Bone Graft Substitute Market, U.S., 2011 - 2021
  • Figure 5-62: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, U.S., 2014
  • Figure 5-63: Leading Competitors, Orthopedic Bone Graft Substitute Market by Segment, U.S.,2014
  • Figure 6-1: Orthopedic Growth Factor Market, U.S., 2011 - 2021
  • Figure 6-2: Drivers and Limiters, Orthopedic Growth Factor Market, U.S., 2014
  • Figure 6-3: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2014
  • Figure 7-1: Orthopedic Stem Cell Market by Anatomy, U.S., 2011 - 2021 (US$M)
  • Figure 7-2: Total Orthopedic Stem Cell Market, U.S., 2011 - 2021
  • Figure 7-3: Cervical Spine Stem Cell Market, U.S., 2011 - 2021
  • Figure 7-4: Lumbar Spine Stem Cell Market, U.S., 2011 - 2021
  • Figure 7-5: Drivers and Limiters, Orthopedic Stem Cell Market, U.S., 2014.
  • Figure 7-6: Leading Competitors, Orthopedic Stem Cell Market, U.S., 2014
  • Figure 8-1: Orthopedic Cell Therapy Market by Segment, U.S., 2011 - 2021 (US$M)
  • Figure 8-2: Total Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-3: Soft Tissue Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-4: Orthopedic Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-5: Cardiac Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-6: Spine Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-7: Plastics Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Figure 8-8: Total Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Figure 8-9: Spine Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Figure 8-10: Trauma Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Figure 8-11: Soft Tissue Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Figure 8-12: Joint Reconstruction Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Figure 8-13: Drivers and Limiters, Orthopedic Cell Therapy Market, U.S., 2014
  • Figure 8-14: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2014
  • Figure 9-1: Orthopedic Hyaluronic Acid Viscosupplementation Market by Segment, U.S.,2011 - 2021 (US$M)
  • Figure 9-2: Total Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Chart 9-3: Total Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Figure 9-4: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021.
  • Figure 9-5: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Figure 9-6: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Figure 9-7: Drivers and Limiters, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S.,
  • 2014
  • Figure 9-8: Leading Competitors, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S.,
  • 2014
  • Figure 10-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2011 - 2021 (US$M)
  • Figure 10-2: Osteochondral Allograft Market, U.S., 2011 - 2021
  • Figure 10-3: Meniscal Allograft Market, U.S., 2011 - 2021
  • Figure 10-4: Autologous Chondrocyte Implantation Market, U.S., 2011 - 2021
  • Figure 10-5: Particulated Juvenile Allograft Implant Market, U.S., 2011 - 2021
  • Figure 10-6: Microfracture Adjunct Market, U.S., 2011 - 2021
  • Figure 10-7: Drivers and Limiters, Orthopedic Cartilage Repair Market, U.S., 2014
  • Figure 10-8: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2014.
  • Figure 11-1: Spinal Machined Bone Allograft Market by Segment, U.S., 2011 - 2021 (US$M)
  • Figure 11-2: Total Spinal Machined Bone Allograft Market, U.S., 2011 - 2021
  • Figure 11-3: ALIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Figure 11-4: PLIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Figure 11-5: TLIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Figure 11-6: CIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Figure 11-7: Drivers and Limiters, Spinal Machined Bone Allograft Market, U.S., 2014
  • Figure 11-8: Leading Competitors, Spinal Machined Bone Allograft Market, U.S., 2014

LIST OF CHARTS

  • Chart 1-1: Orthopedic Biomaterials Market, U.S., 2011 - 2021
  • Chart 1-2: Orthopedic Bone Graft Substitute Market Growth by Segment, U.S., 2014, 2017 and 2021
  • Chart 1-3: Orthopedic Growth Factor Market, U.S., 2011, 2014, 2017 and 2021
  • Chart 1-4: Orthopedic Stem Cell Market by Segment, U.S., 2014 and 2021
  • Chart 1-5: Orthopedic Cell Therapy Market by Segment, U.S., 2011 - 2021
  • Chart 1-6: Orthopedic Hyaluronic Acid Viscosupplementation Market Breakdown by Segment, U.S.,2011, 2014, 2017 and 2021
  • Chart 1-7: Orthopedic Cartilage Repair Market by Segment, U.S., 2014
  • Chart 1-8: Spinal Machined Bone Allograft Market by Segment, U.S., 2013 - 2015
  • Chart 1-9: Leading Competitors, Orthopedic Biomaterials Market U.S., 2014
  • Chart 3-1: Orthopedic Biomaterials Market by Segment, U.S., 2011 - 2021
  • Chart 3-2: Orthopedic Biomaterials Market Breakdown, U.S., 2014
  • Chart 3-3: Orthopedic Biomaterials Market Breakdown, U.S., 2021
  • Chart 3-4: Orthopedic Biomaterials Market Growth by Segment, U.S., 2011 - 2021
  • Chart 3-5: Leading Competitors, Orthopedic Biomaterials Market, U.S., 2014
  • Chart 3-6: Herfindahl Index, Orthopedic Biomaterials Market, U.S., 2014
  • Chart 4-1: Bone Graft Procedure Numbers By Type, U.S., 2011 - 2021
  • Chart 4-2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2011 - 2021.
  • Chart 4-3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2011 - 2021
  • Chart 4-4: Growth Factor Bone Graft Procedure Numbers, U.S., 2011 - 2021
  • Chart 4-5: Stem Cell Bone Graft Procedure Numbers, U.S., 2011 - 2021
  • Chart 4-6: Cell Therapy Treatment Numbers by Type, U.S., 2011 - 2021
  • Chart 4-7: Platelet-Rich Plasma Treatment Numbers By Indication, U.S., 2011 - 2021
  • Chart 4-8: Bone Marrow Concentrate Treatment Numbers By Indication, U.S., 2011 - 2021
  • Chart 4-9: Hyaluronic Acid Treatment Numbers By Type, U.S., 2011 - 2021
  • Chart 4-10: Cartilage Repair Procedure Numbers By Type, U.S., 2011 - 2021
  • Chart 4-11: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2011 - 2021
  • Chart 5-1: Bone Graft Substitute Procedure Numbers By Material, U.S., 2011 - 2021
  • Chart 5-2: Orthopedic Bone Graft Substitute Market by Material, U.S., 2011 - 2021
  • Chart 5-3: Orthopedic Bone Graft Substitute Market Breakdown by Material, U.S., 2014.
  • Chart 5-4: Orthopedic Bone Graft Substitute Market Breakdown by Material, U.S., 2021.
  • Chart 5-5: Orthopedic Bone Graft Substitute Market by Indication, U.S., 2011 - 2021
  • Chart 5-6: Orthopedic Bone Graft Substitute Market Breakdown by Indication, U.S., 2014
  • Chart 5-7: Orthopedic Bone Graft Substitute Market Breakdown by Indication, U.S., 2021
  • Chart 5-8: Total Orthopedic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-9: Total Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-10: Allograft Bone Graft Substitute Market by Indication, U.S., 2011 - 2021
  • Chart 5-11: Total Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-12: Cervical Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-13: Thoracolumbar Spine Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-14: Total Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-15: Non-union Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-16: Fresh Fracture Trauma Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-17: Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-18: Hip Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S.,2011 - 2021
  • Chart 5-19: Knee Large Joint Reconstruction Allograft Bone Graft Substitute Market, U.S.,2011 - 2021
  • Chart 5-20: Foot Reconstruction Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-21: Craniomaxillofacial Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-22: Oncology Allograft Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-23: Total Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-24: Demineralized Bone Matrix Market by Indication, U.S., 2011 - 2021
  • Chart 5-25: Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-26: Cervical Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-27: Thoracolumbar Spine Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-28: Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-29: Non-union Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-30: Fresh Fracture Trauma Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-31: Large Joint Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-32: Large Joint Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-33: Knee Large Joint Reconstruction Demineralized Bone Matrix Market, U.S.,2011 - 2021
  • Chart 5-34: Foot Reconstruction Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-35: Craniomaxillofacial Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-36: Oncology Demineralized Bone Matrix Market, U.S., 2011 - 2021
  • Chart 5-37: Total Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-38: Synthetic Bone Graft Substitute Market by Indication, U.S., 2011 - 2021
  • Chart 5-39: Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-40: Cervical Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-41: Thoracolumbar Spine Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-42: Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-43: Non-union Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-44: Fresh Fracture Trauma Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-45: Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-46: Hip Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S.,2011 - 2021
  • Chart 5-47: Knee Large Joint Reconstruction Synthetic Bone Graft Substitute Market, U.S.,2011 - 2021
  • Chart 5-48: Foot Reconstruction Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-49: Craniomaxillofacial Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-50: Oncology Synthetic Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-51: Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-52: Cervical Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-53: Thoracolumbar Spine Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-54: Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-55: Non-union Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-56: Fresh Fracture Trauma Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-57: Large Joint Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-58: Hip Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-59: Knee Large Joint Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-60: Foot Reconstruction Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-61: Craniomaxillofacial Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-62: Oncology Bone Graft Substitute Market, U.S., 2011 - 2021
  • Chart 5-63: Leading Competitors, Orthopedic Bone Graft Substitute Market, U.S., 2014
  • Chart 6-1: Orthopedic Growth Factor Market, U.S., 2011 - 2021
  • Chart 6-2: Leading Competitors, Orthopedic Growth Factor Market, U.S., 2014
  • Chart 7-1: Orthopedic Stem Cell Market by Anatomy, U.S., 2011 - 2021
  • Chart 7-2: Total Orthopedic Stem Cell Market, U.S., 2011 - 2021
  • Chart 7-3: Cervical Spine Stem Cell Market, U.S., 2011 - 2021
  • Chart 7-4: Lumbar Spine Stem Cell Market, U.S., 2011 - 2021
  • Chart 7-5: Leading Competitors, Orthopedic Stem Cell Market, U.S., 2014
  • Chart 8-1: Orthopedic Cell Therapy Market by Segment, U.S., 2011 - 2021
  • Chart 8-2: Orthopedic Cell Therapy Market Breakdown, U.S., 2014
  • Chart 8-3: Orthopedic Cell Therapy Market Breakdown, U.S., 2021
  • Chart 8-4: Total Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-5: Soft Tissue Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-6: Orthopedic Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-7: Cardiac Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-8: Spine Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-9: Plastics Platelet-Rich Plasma Market, U.S., 2011 - 2021
  • Chart 8-10: Total Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Chart 8-11: Spine Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Chart 8-12: Trauma Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Chart 8-13: Soft Tissue Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Chart 8-14: Joint Reconstruction Bone Marrow Concentrate Market, U.S., 2011 - 2021
  • Chart 8-15: Leading Competitors, Orthopedic Cell Therapy Market, U.S., 2014
  • Chart 9-1: Orthopedic Hyaluronic Acid Viscosupplementation Market by Segment, U.S.,2011 - 2021
  • Chart 9-2: Orthopedic Hyaluronic Acid Viscosupplementation Market Breakdown, U.S., 2014
  • Chart 9-3: Orthopedic Hyaluronic Acid Viscosupplementation Market Breakdown, U.S., 2021
  • Chart 9-4: Single-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Chart 9-5: Three-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Chart 9-6: Five-Injection Hyaluronic Acid Viscosupplementation Market, U.S., 2011 - 2021
  • Chart 9-7: Leading Competitors, Orthopedic Hyaluronic Acid Viscosupplementation Market, U.S.,2014
  • Chart 10-1: Orthopedic Cartilage Repair Market by Segment, U.S., 2011 - 2021
  • Chart 10-2: Orthopedic Cartilage Repair Market Breakdown, U.S., 2014
  • Chart 10-3: Orthopedic Cartilage Repair Market Breakdown, U.S., 2021
  • Chart 10-4: Osteochondral Allograft Market, U.S., 2011 - 2021
  • Chart 10-5: Meniscal Allograft Market, U.S., 2011 - 2021
  • Chart 10-6: Autologous Chondrocyte Implantation Market, U.S., 2011 - 2021
  • Chart 10-7: Particulated Juvenile Allograft Implant Market, U.S., 2011 - 2021
  • Chart 10-8: Microfracture Adjunct Market, U.S., 2011 - 2021
  • Chart 10-9: Leading Competitors, Orthopedic Cartilage Repair Market, U.S., 2014
  • Chart 11-1: Spinal Machined Bone Allograft Market by Segment, U.S., 2011 - 2021
  • Chart 11-2: Spinal Machined Bone Allograft Market Breakdown, U.S., 2014.
  • Chart 11-3: Spinal Machined Bone Allograft Market Breakdown, U.S., 2021.
  • Chart 11-4: Total Spinal Machined Bone Allograft Market, U.S., 2011 - 2021
  • Chart 11-5: ALIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Chart 11-6: PLIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Chart 11-7: TLIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Chart 11-8: CIF Machined Bone Allograft Market, U.S., 2011 - 2021
  • Chart 11-9: Leading Competitors, Spinal Machined Bone Allograft Market, U.S., 2014
Back to Top